Ofev 150 — Nintedanib 150 mg (60 Capsules)
Ofev 150 mg (Nintedanib) is an innovative targeted medication designed for the treatment of severe fibrosing lung diseases. The active substance, nintedanib, is a potent tyrosine kinase inhibitor. It blocks the receptors responsible for the proliferation of connective tissue in the lungs, thereby slowing down the "scarring" process (fibrosis). The 150 mg dosage is the primary therapeutic dose, providing maximum control over disease progression.
Manufacturer: Boehringer Ingelheim, Germany. Ofev 150 significantly reduces the rate of decline in forced vital capacity and decreases the risk of acute pulmonary exacerbations, which can be life-threatening. The drug allows for slowing the disease progression and helps patients maintain physical activity longer.
Key Features:
- ✅ Maximum Concentration: The 150 mg dosage provides optimal anti-fibrotic action according to international protocols.
- ✅ Slowing Fibrosis: Direct impact on growth factors (VEGFR, FGFR, PDGFR) that cause pathological changes in the lungs.
- ✅ Clinical Standard: The primary medication for the therapy of idiopathic pulmonary fibrosis worldwide.
Ofev 150 mg is used for the pathogenetic treatment of adult patients with the following diagnoses:
- 🔹 Idiopathic Pulmonary Fibrosis (IPF): To slow the progression of scarring in the lung tissue.
- 🔹 Progressive Fibrosing Interstitial Lung Diseases (ILD): With a chronic course phenotype.
- 🔹 Systemic Sclerosis: Treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Sales Form: 1 pack contains 60 soft capsules of 150 mg.
⚠️ INSTRUCTIONS FOR USE:
- Dosage Regimen: The standard dose is 150 mg (1 capsule) twice daily (morning and evening) with a 12-hour interval.
- Method: Capsules should be taken orally with food, swallowed whole. Do not chew, break, or open the capsule.
- Monitoring: During Ofev 150 therapy, it is necessary to regularly (once a month at the beginning of treatment) check liver function tests (ALT, AST, bilirubin).
- Dose Adjustment: In case of severe side effects (e.g., severe diarrhea), the doctor may temporarily reduce the dose to 100 mg or suspend treatment.
- Storage: Store at a temperature not exceeding 25°C in the original packaging to protect from moisture.
- ⛔ Pregnancy: Nintedanib has teratogenic effects. Use during pregnancy is strictly prohibited.
- ⛔ Hepatic Impairment: Moderate to severe hepatic insufficiency (Child-Pugh classes B and C).
- ⛔ Allergy: Hypersensitivity to nintedanib, as well as to peanuts or soy (excipients in the capsule composition).
- ⛔ Age: Not for use in children and adolescents under 18 years of age.
- ⛔ Lactation: Breastfeeding should be discontinued during the therapy period.
When using the 150 mg dosage, side effects are common, but in most cases, they are manageable:
- 🤢 Gastrointestinal Tract: Diarrhea (most common), nausea, vomiting, decreased appetite, abdominal pain.
- 🧪 Liver: Increased levels of liver transaminases (ALT/AST).
- 🩸 Vessels: Increased blood pressure; in rare cases — risk of thromboembolic complications.
- 📉 Weight: Weight loss due to gastrointestinal disorders.
- ⚠️ Important: If diarrhea occurs, it is recommended to immediately start taking anti-diarrheal agents (loperamide) and increase fluid intake. If symptoms persist, consult a physician.
Similar products
What Customers Say
No reviews yet
Your review can be the first!